Artificial Intelligence driven Marketing Communications
“NEW PRODUCT LAUNCH” Silver Magnolia Medcal Products, which was organized for the design and manufacture of medical products to aid the elderly in correctly take their medications. The “Home Med Station” is complete, and first 1000 units delivered.
Silver Magnolia Medical Products, has completed Phase-I and is beginning Phase-II of the company development. We are establishing Sales and Distribution Channels.
Medication not taken as prescribed by the Health Care Professional also known as Non-Compliance is a 300-billion-dollar loss per year to the US Health Care System (New England Medical Institute, 2015).
The Home Med Station is a unique drug management solution to aid patients in Compliance of their prescription medicines. This is the only complete system available worldwide, that will assist the senior population in maintaining compliance with their medication. Our patented features are integrated to allow lockable pill vial storage, weekly pill medicine dispensers, digital alarms, communication area for symptom recording and doctor’s diagnostic review.
Our marketing target will be the 65 and older population which constitutes 45 million or 14.5% of US population in 2015. We estimate we will be able to supply between 4% and 5% of this target which will be 1.8 – 2.2 million people. We estimate that we should be able to achieve an average of 120,000 – 180,000 per year by the 5th year. Our projection for the 3rd year will be estimated at 60,000 units sold.
Our gross profit is $55 – $68 per unit. This project will generate a net profit of 2.5MM after taxes for the 3rd year.
Currently we will offer a $1.00 per share or $200,000 for 10 % equity in the company. The minimum investment will be $25,000. Our projected share valve at end of 3rd year will be
$4.00 – $8.00 per share based on our 2.5 million net profit projection.
In addition to the above marketing target of the 65 and older seniors which we plan to sale through national medical distributors, we are developing strategy alliances with pharmaceutical and health insurance companies. With this marketing strategy, will be able to add more diverse groups of medical patients
The best means for contact:
The Home Med Station (HMS) has been designed as a complete center to aid a patient in maintaining compliance with their medication regimes. It was invented by Vincent Mauk to aid his mother in maintain compliance with her prescribed medications. The design was refined over a two-year period with input from her Doctor, Nurses and Home Health Care organization. She was able to stay in her own home for an additional three years.
The HMS is protected by US patent #7,584,849 published on Sept. 08, 2009 & Patent Pending #62/233,200 filed on Sept. 25, 2015. The original patent was awarded the “Best Patent of 2010”, in the Greater Houston Metro Area.
The HMS is fabricated out of medically accepted plastics and has been giving approval by the FDA as a 510K product.
The preferred path that has been established by Medicare is “Aging in Place”, this meaning that an elderly patient should stay at their own homes, until being limited by mental or physical concerns.
Mr. Vincent Mauk is President and Chief Technology Officer for DME. He graduated from Texas A&M University in 1988 with a degree in Mechanical Engineer Technology. Vincent has worked as a Project Engineer for 13 years and Engineering Manager for 18 years on a wide variety of engineering projects.
Mr. Andy Hu obtained his Master’s degree in Engineering/Project Management from the University of Florida in 1982. He has more than 28 years of experience in the medical industry. Through years of interaction with major public medical device companies in the US, Japan and Taiwan, Mr. Hu has accumulated versatile, well-rounded knowledge and experience in creating and increasing the value of a company.
Mr. Mike Reedman career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. He has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international.